Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **nucleus pulposus extracellular matrix** is the hydrated, gelatinous matrix at the center of the intervertebral disc, essential for spine flexibility and shock absorption. It consists primarily of water, proteoglycans (notably aggrecan), type II collagen, glycoproteins, and elastin, produced and maintained by nucleus pulposus cells. The ECM provides resistance to compressive forces, maintains structural integrity, and supports specialized cellular phenotypes by mediating mechanical and biochemical cues. Its slow molecular turnover makes it vulnerable to age- and injury-related degeneration, with loss of proteoglycans and collagen, increased matrix-degrading activity (MMPs, ADAMTS), and impaired repair capacity being hallmarks of disc degeneration, which leads to chronic back pain and disability.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleus pulposus extracellular matrix.